| Name | Picolinamide |
| Description | Picolinamide (Picolinoylamide) is found to be a strong inhibitor of poly (ADP-ribose) synthetase of nuclei from rat pancreatic islet cells. |
| In vitro | In AR-HEK293 cells stably expressing full-length hAR, ODM-201 inhibits human AR (hAR) with IC50 of 26 nM. ODM-201 inhibits VCaP cell proliferation with IC50 of 230 nM, while has no effect on the viability of AR-negative cell lines tested, DU-145 prostate cancer cells and H1581 lung cancer cells. [1] |
| In vivo | Overnight treatment of rats with picolinamide, administered as a single injection (4 mmol/kg), inhibits Na+/phosphate cotransport by isolated renal brush border membrane vesicles. There is only a small increase (1.5-fold) in renal cortical NAD content after picolinamide treatment[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 23 mg/mL (188.34 mM), Sonication is recommended. DMSO : 45 mg/mL (368.49 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (16.38 mM), Sonication is recommended. H2O : 22 mg/mL (180.15 mM), Sonication is recommended.
|
| Keywords | Picolinamide | PARP |
| Inhibitors Related | Niraparib tosylate monohyrate | 7-Methylguanine | VPC-70063 | 3-Aminobenzamide | XAV-939 | Niraparib | AZ9482 | Sodium taurodeoxycholate hydrate | RMC-7977 | Olaparib | Benzamide | OUL35 |
| Related Compound Libraries | Bioactive Compound Library | Epigenetics Compound Library | Anti-Breast Cancer Compound Library | Anti-Ovarian Cancer Compound Library | Tobacco Monomer Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Anti-Cardiovascular Disease Compound Library | Cosmetic Ingredient Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Human Metabolite Library |